Skip to main content

Table 1 Clinical characteristics

From: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients

Characteristics Patients
N (%)  
Gender  
 Male 18 (53%)
 Female 16 (47%)
Age (median, range) 60 (29–85)
ECOG PS  
 0 2 (6%)
 1 17 (50%)
 2 12 (35%)
 3 3 (9%)
Tumour site  
 Stomach 11 (32.4%)
 Small Intestine 10 (29.4%)
 Mesentery 7 (20.6%)
 Other 6 (17.6%)
 (peritoneum3, colon 1, rectum 1, oesophagus 1)  
Metastatic sites  
 Liver 28 (82%)
 Peritoneum 25 (73.5%)
 Lung 4 (12%)
 Other 10 (29.5%)
Transfusion before EPO treatment  
 Yes 10 (29%)/
 No 24 (71%)
Starting Dose of Imatinib/day  
 400 mg 25(67.6%)
 800 mg 9(11.7%)